Barclays Downgrades Myriad Genetics (MYGN) to Equalweight

August 10, 2016 7:40 AM EDT
Get Alerts MYGN Hot Sheet
Price: $17.40 +2.41%

Rating Summary:
    7 Buy, 16 Hold, 6 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade MYGN Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Barclays downgraded Myriad Genetics (NASDAQ: MYGN) from Overweight to Equalweight with a price target of $24.00 (from $50.00).

For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.

Shares of Myriad Genetics closed at $29.46 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst PT Change, Downgrades

Related Entities

Barclays

Add Your Comment